PCI Biotech is a biopharmaceutical company focusing on its innovative photochemical internalisation (PCI) technology platform. PCI releases molecules trapped in endosomes into the cytosol through endosomal escape triggered by illumination, making it possible to site-direct enhanced therapeutic effects.
The PCI technology is utilized in a vaccination platform named fimaVACC, applied for enhancing cellular immune responses, mainly directed at CTL responses. By releasing antigens (peptides and proteins) from endosomes, MHC Class I presentation is enhanced, strongly stimulating antigen specific CTL responses. In addition, fimaVACC enhances helper T-cell and antibody responses.